Viewing Study NCT04447118

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:30 AM
Ignite Modification Date: 2026-01-29 @ 9:31 AM
Study NCT ID: NCT04447118
Status: COMPLETED
Last Update Posted: 2025-12-19
First Post: 2020-06-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-squamous NSCLC View
None HER2 Exon 20 Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pyrotinib View
None docetaxel View
None HER2 Exon 20 Mutation View
None NSCLC View